Table 5 |
||||||
| Treatment exposure in respondersand non-responders | ||||||
| WT KRAS (n = 85) | MT KRAS (n = 58) | Overalla(n = 152) | ||||
| Responders (n = 48) | Non-responders (n = 37) | Responders (n = 22) | Non-responders (n = 36) | Responders (n = 75) | Non-responders (n = 77) | |
| Panitumumab cycles delivered – mean (SD) | 16.3 (6.6) | 9.2 (6.9) | 15.0 (6.4) | 8.5 (4.4) | 15.8 (6.6) | 8.7 (5.7) |
| Cumulative panitumumab dose deliveredb, mg/kg - mean (SD) | 94.2 (37.0) | 55.2 (41.5) | 83.5 (37.4) | 49.8 (26.2) | 89.8 (37.5) | 51.4 (34.2) |
| Irinotecan cycles delivered mean (SD) | 15.6 (6.0) | 9.5 (6.3) | 15.7 (4.8) | 9.3 (4.5) | 15.5 (5.7) | 9.4 (5.4) |
| Cumulative irinotecan dose deliveredb, mg/kg - mean (SD) | 2635 (1012) | 1614 (1026) | 2603 (754) | 1542 (722) | 2605 (954) | 1569 (869) |
Responders comprise those patients with a best overall response of a complete or partial response; non-responders comprise those patients with a best overall response of stable disease, disease progression or those with no post-baseline response assessment.
aAll patients in the tumour response analysis set regardless of KRAS evaluability; bAdjusted for weight or BSA (most recent measurement before infusion).
Thaler et al. BMC Cancer 2012 12:438 doi:10.1186/1471-2407-12-438
